Alpha-synuclein
therapies will be available sooner to treat symptoms and slow disease progression .
The new tools also open the door to interventions that can disrupt the disease biology earlier — even before symptoms ever have the chance to develop .
As the new biomarker and staging system now start being integrated into clinical trials and other research , here is an overview of the most promising , closely watched therapies in the pipeline for MJFF and our community :
Alpha-synuclein
The new biomarker is flowing directly into trials targeting underlying PD biology . Its use can ensure that trials targeting
5 Years 20 Years 25 Years
FDA approval and commercialization
FDA approval and commercialization
17